Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

94 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Thromboembolic events and antithrombotic prophylaxis in advanced ovarian cancer patients treated with bevacizumab: secondary analysis of the phase IV MITO-16A/MaNGO-OV2A trial.
Di Liello R, Arenare L, Raspagliesi F, Scambia G, Pisano C, Colombo N, Frezzini S, Tognon G, Artioli G, Gadducci A, Lauria R, Ferrero A, Cinieri S, De Censi A, Breda E, Scollo P, De Giorgi U, Lissoni AA, Katsaros D, Lorusso D, Salutari V, Cecere SC, Lapresa M, Nardin M, Bogani G, Distefano M, Greggi S, Gargiulo P, Schettino C, Gallo C, Daniele G, Califano D, Perrone F, Pignata S, Piccirillo MC. Di Liello R, et al. Among authors: califano d. Int J Gynecol Cancer. 2021 Oct;31(10):1348-1355. doi: 10.1136/ijgc-2021-002786. Epub 2021 Aug 30. Int J Gynecol Cancer. 2021. PMID: 34462317 Clinical Trial.
Significance of erb-B2 immunoreactivity in cervical cancer.
Califano D, Losito S, Pisano C, Santelli G, Greggi S, Iodice F, DiVagno G, Silvestro G, Tambaro R, Formato R, Iaffaioli VR, Di Maio M, Pignata S. Califano D, et al. Front Biosci. 2006 Sep 1;11:2071-6. doi: 10.2741/1949. Front Biosci. 2006. PMID: 16720293
FEZ1/LZTS1 protein expression in ovarian cancer.
Califano D, Pignata S, Pisano C, Greggi S, Laurelli G, Losito NS, Ottaiano A, Gallipoli A, Pasquinelli R, De Simone V, Cirombella R, Fusco A, Chiappetta G. Califano D, et al. J Cell Physiol. 2010 Feb;222(2):382-6. doi: 10.1002/jcp.21962. J Cell Physiol. 2010. PMID: 19885841
Development and validation of a microRNA-based signature (MiROvaR) to predict early relapse or progression of epithelial ovarian cancer: a cohort study.
Bagnoli M, Canevari S, Califano D, Losito S, Maio MD, Raspagliesi F, Carcangiu ML, Toffoli G, Cecchin E, Sorio R, Canzonieri V, Russo D, Scognamiglio G, Chiappetta G, Baldassarre G, Lorusso D, Scambia G, Zannoni GF, Savarese A, Carosi M, Scollo P, Breda E, Murgia V, Perrone F, Pignata S, De Cecco L, Mezzanzanica D; Multicentre Italian Trials in Ovarian cancer (MITO) translational group. Bagnoli M, et al. Among authors: califano d. Lancet Oncol. 2016 Aug;17(8):1137-1146. doi: 10.1016/S1470-2045(16)30108-5. Epub 2016 Jul 9. Lancet Oncol. 2016. PMID: 27402147 Free article.
Biomarker analysis of the MITO2 phase III trial of first-line treatment in ovarian cancer: predictive value of DNA-PK and phosphorylated ACC.
Perrone F, Baldassarre G, Indraccolo S, Signoriello S, Chiappetta G, Esposito F, Ferrandina G, Franco R, Mezzanzanica D, Sonego M, Zulato E, Zannoni GF, Canzonieri V, Scambia G, Sorio R, Savarese A, Breda E, Scollo P, Ferro A, Tamberi S, Febbraro A, Natale D, Di Maio M, Califano D, Scognamiglio G, Lorusso D, Canevari S, Losito S, Gallo C, Pignata S. Perrone F, et al. Among authors: califano d. Oncotarget. 2016 Nov 8;7(45):72654-72661. doi: 10.18632/oncotarget.12056. Oncotarget. 2016. PMID: 27655643 Free PMC article. Clinical Trial.
Trabectedin in Ovarian Cancer: is it now a Standard of Care?
Ventriglia J, Paciolla I, Cecere SC, Pisano C, Di Napoli M, Arenare L, Setola SV, Losito NS, Califano D, Orditura M, Pignata S. Ventriglia J, et al. Among authors: califano d. Clin Oncol (R Coll Radiol). 2018 Aug;30(8):498-503. doi: 10.1016/j.clon.2018.01.008. Epub 2018 Feb 9. Clin Oncol (R Coll Radiol). 2018. PMID: 29429842 Review.
94 results